drugset
drugset / Trial / NCT07055529

Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

NCT07055529 ↗

Phase 0 Not yet recruiting 64 enrolled Hayat Abad Medical Complex, Peshawar
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Timeline

Start
2026-06-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Psoralen Small molecule — Oral
Subject Tofacitinib Small molecule 5 mg Oral

Indications

generalized vitiligo